ArticleThe American journal of drug and alcohol abuse2018
Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
Article in The American journal of drug and alcohol abuse, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Buprenorphine and Surface-based Brain Morphometry: Impacts on Cortical Thickness, Depth, and Gyrification in Patients with Opioid Use Disorder.Indian journal of psychological medicine · 2025Article
- Racial, ethnic, and sex disparities in buprenorphine treatment from emergency departments by discharge diagnosis.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025Article
- Delayed estrogen actions diminish food consumption without changing food approach, motor activity, or hypothalamic activation elicited by corticostriatal µ-opioid signaling.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Gender-Specific Interactions in a Visual Object Recognition Task in Persons with Opioid Use Disorder.Biomedicines · 2023Article
- Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice.Behavioural brain research · 2023Article
- Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice.bioRxiv : the preprint server for biology · 2023Article
- Fentanyl-induced reward seeking is sex and dose dependent and is prevented by D-cysteine ethylester.Frontiers in pharmacology · 2023Article
- Sex, gender, and the opioid epidemic: Crucial implications for acute care.AEM education and training · 2022Article
- Sex and Gender Differences in the Effects of Novel Psychoactive Substances.Brain sciences · 2020Review
- Vaccine blunts fentanyl potency in male rhesus monkeys.Neuropharmacology · 2019Article
- Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.Drug and alcohol dependence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThere are sex differences in buprenorphine/naloxone clinical trials for opioid use. While women have fewer opioid-positive urine samples, relative to men, a significant decrease in opioid-positive samples was found during treatment for men, but not women. In order to inform sex-based approaches to improve treatment outcomes, research is needed to determine if opioid use, and predictors of opioid use, differs between men and women during treatment.
objectivesTo test for sex differences in opioid use during a buprenorphine/naloxone clinical trial and determine if sex differences exist in the associations between addiction-related problem areas and opioid use over the course of the trial.
methodThis secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003 examined sex differences (men = 347, women = 169) in opioid-positive samples in a randomized clinical trial comparing 7-day vs. 28-day buprenorphine/naloxone tapering strategies. Addiction-related problem areas were defined by Addiction Severity-Lite (ASI-L) domain composite scores.
resultsWomen were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial (B = .33, p = .01) and medical issues were positively related to submitting an opioid-positive sample during treatment for women (B = 1.67, p = .01). No ASI-L domain composite score was associated with opioid-positive samples during treatment for men.
conclusionWomen were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial, and medical issues predicted opioid use during treatment for women but not men. Complementary treatment for medical problems during opioid replacement therapy may benefit women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.